A Qatar-based study involving 121,700 patients has underscored the importance of the post-vaccination monitoring to optimise ...

During a live event, Thomas LeBlanc, MD, MA, discussed dose escalation of luspatercept in myelodysplastic syndromes and ...

SIGNIFICANT EVENTS DURING 1 APRIL - 30 JUNE 2025In April, Iconovo announced an organizational change expected to reduce annual costs by approximately 14-16 MSEK starting in the third quarter of 2025.

The selection of a first-line treatment for patients with advanced EGFR -positive non-small cell lung cancer (NSCLC) has ...

Dizal will market sunvozertinib in the US under the Zegfrovy brand name, entering a market for EGFR inhibitors currently dominated by AstraZeneca's Tagrisso (osimertinib) but currently being shaken up ...

With over 600 million Chinese adults projected to be overweight by 2050, the emergence of a viable local alternative to Novo and Lilly’s blockbuster GLP-1 treatments could make weight loss drugs more ...

A man has tested positive for Covid-19 after arriving in Hobart via a Brisbane flight. It comes after Queensland reached its 70 per cent double dose milestone. The Premier has warned residents on the ...

The biotech sector remains one of the most dynamic areas of the market, driven by clinical breakthroughs, regulatory decisions, and disruptive innovations. Over the years, large pharmaceutical ...

With an FDA IND clearance, the firm will test IKS014 as an alternative for HER2-positive solid tumor patients in the US who have relapsed on other therapies.

Despite a Q1 revenue miss due to currency headwinds, core EPS beat expectations for AstraZeneca. Read why AZN stock is a Buy.

Summit Therapeutics nears a $15B AstraZeneca deal for ivonescimab, targeting a $90B market. See more on the potential and ...

Johnson & Johnson announced Tuesday that a second dose of its COVID-19 vaccine given at two months provides 94% protection against the coronavirus in the United States. Johnson & Johnson released ...